1. Home
  2. TOPS vs MBIO Comparison

TOPS vs MBIO Comparison

Compare TOPS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Ships Inc.

TOPS

TOP Ships Inc.

HOLD

Current Price

$0.74

Market Cap

4.9M

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.54

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOPS
MBIO
Founded
2000
2015
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.2M
IPO Year
2004
2023

Fundamental Metrics

Financial Performance
Metric
TOPS
MBIO
Price
$0.74
$0.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
121.4K
22.7K
Earning Date
04-01-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$0.52
52 Week High
$7.40
$1.84

Technical Indicators

Market Signals
Indicator
TOPS
MBIO
Relative Strength Index (RSI) 44.20 37.66
Support Level $0.73 $0.53
Resistance Level $0.87 $0.66
Average True Range (ATR) 0.06 0.02
MACD -0.00 -0.00
Stochastic Oscillator 5.19 0.00

Price Performance

Historical Comparison
TOPS
MBIO

About TOPS TOP Ships Inc.

TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco-tanker vessels, focusing on the transportation of crude oil, petroleum products (both clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements. The company operates in two reportable segments: (i) the tanker segment and (ii) the megayacht segment.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: